DrugDashboards

Kerendia

finerenone · FINERENONE 20 mg/1 · Tablet, Film Coated · Oral · Bayer HealthCare Pharmaceuticals Inc.

NDC 50419-0541-01 · 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $22.84 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$22.84per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$21.06per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$22.90per unitnegotiated price across 5,496 plans — before rebates · Apr 1, 2026
  • Federal ceiling (Big4)$16.76per unitBayer HealthCare Pharmaceuticals, Inc. · Jan 1, 202673% of what pharmacies pay — a deeper discount than 71% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$22.90per unit
middle half $22.61$23.99 · 5,496 plans · Apr 1, 2026
Est. net of rebates
$13.74–$17.17
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 60% · step therapy 0% · qty limit 95%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$10.00$20.00$30.00Jan 2022Sep 2026$22.84
28 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$685.24
#90 count
$2055.73

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$18.4M
23,081 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for finerenone (oral solid) in the next 90 days

sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 3 across plans
  • Costs ≥ $950/fill · avg $981.98 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA215341
TE code
Approval date
Jul 9, 2021
Patents / exclusivity
6 patents, 6 exclusivities
TypeNumber / codeExpires
exclusivityNSJul 11, 2028
exclusivityI-970Jul 11, 2028
exclusivityI-970Jul 11, 2028
exclusivityNCEJul 9, 2026
exclusivityNCEJul 9, 2026
exclusivityNCEJul 9, 2026
patentRE49826Jul 29, 2035
patentRE49826Jul 29, 2035
patentRE49826Jul 29, 2035
patent8436180Aug 26, 2033
patent8436180Aug 26, 2033
patent8436180Aug 26, 2033

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of finerenone (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Bayer AGFINERENONE 10 mg/1Jul 15, 2026Sep 2, 2026
Bayer AGFINERENONE 20 mg/1Jul 15, 2026Sep 2, 2026
Bayer HealthCare Pharmaceuticals Inc.FINERENONE 10 mg/1Jul 15, 2026Sep 2, 2026
Bayer HealthCare Pharmaceuticals Inc.FINERENONE 20 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Kerendia — NDC 50419-0541-01," retrieved September 3, 2026, https://drugdashboards.com/drug/50419054101.

Free to cite with attribution — see how the data is put together.